ycliper

Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
Скачать

Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017

REdI

CDER

FDA

SBIA

IND

InvestigationalNewDrug

Автор: U.S. Food and Drug Administration

Загружено: 2020-08-06

Просмотров: 26595

Описание: Maria Cecilia Tami and Balajee Shanmugam review the Chemistry, Manufacturing and Controls (CMC) portion of a drug intended for use under an investigational new drug application (IND). The review resides in the Office of New Drug Products (ONDP) and in the Office of Biotechnological Products (OBP). ONDP reviews small molecules while biologics are reviewed by OBP.
This session discusses the CMC information for small molecules and biologics required for an IND per 21 CFR 312.23, especially with reference to the drug substance (characterization, manufacturing, testing, and stability) and drug product (composition, manufacture, testing and stability), to support that the investigational drug is reasonably safe for use in a clinical trial. The presentation will also discuss case studies of CMC related clinical hold issues.
-------------------------

FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.

Upcoming training and free continuing education credits: https://www.fda.gov/cdersbia

CDER SBIA 2017 Playlist:    • 2017 CDER Small Business and Industry Assi...  
LinkedIn:   / cder-small-business-and-industry-assistance  
Training resources: https://www.fda.gov/cderbsbialearn

Twitter:   / fda_drug_info  

CDER small business e-mail update subscription: https://updates.fda.gov/subscriptionm...

Email: [email protected]
Phone: (301) 796-6707 I (866) 405-5367

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017

Поделиться в:

Доступные форматы для скачивания:

Скачать видео

  • Информация по загрузке:

Скачать аудио

Похожие видео

Overview of Non-clinical Assessment in Drug Development (8/14) REdI 2017

Overview of Non-clinical Assessment in Drug Development (8/14) REdI 2017

Chemistry, Manufacturing, and Controls (CMC) for an IND (7of14) REdI 2018

Chemistry, Manufacturing, and Controls (CMC) for an IND (7of14) REdI 2018

Post-approval Considerations for Changes to Manufacturing Process and Facilities - REdI 2020

Post-approval Considerations for Changes to Manufacturing Process and Facilities - REdI 2020

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA Expert Panel on Testosterone Replacement Therapy for Men

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

CMC - NDA requirements and Common Pitfalls of BLAs (14of15) REdI – May 29-30, 2019

CMC - NDA requirements and Common Pitfalls of BLAs (14of15) REdI – May 29-30, 2019

Pharmaceutical Quality Symposium 2023 - Day 1

Pharmaceutical Quality Symposium 2023 - Day 1

Microbiology Assessment: Recommendations for Nonsterile Products (1of6) Mar. 15, 2017

Microbiology Assessment: Recommendations for Nonsterile Products (1of6) Mar. 15, 2017

Overview of Post-approval Chemistry, Manufacture, and Controls (CMC) Changes to an NDA - REdI 2020

Overview of Post-approval Chemistry, Manufacture, and Controls (CMC) Changes to an NDA - REdI 2020

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018

CMC Considerations for CAR T Cell Product Development

CMC Considerations for CAR T Cell Product Development

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018

Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018

Process Validation and ICH Q7

Process Validation and ICH Q7

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

NDA and BLA Application Review Process (6of15) REdI Annual Conference – May 29-30, 2019

NDA and BLA Application Review Process (6of15) REdI Annual Conference – May 29-30, 2019

Medical Device Quality Management System Regulation Design and Development

Medical Device Quality Management System Regulation Design and Development

Synthetic Therapeutic Peptide APIs: Documentation for API Sameness & Related Impurities

Synthetic Therapeutic Peptide APIs: Documentation for API Sameness & Related Impurities

Introduction to Investigational New Drug (IND) Applications (3/14) REdI 2017

Introduction to Investigational New Drug (IND) Applications (3/14) REdI 2017

© 2025 ycliper. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]